Attacking malignant cells that survive therapy: Exploiting immunogenic modulation. - Wikidata - awgldk - TriplyDB

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.

http://www.wikidata.org/entity/Q37515914

about

Neoadjuvant nab-paclitaxel in the treatment of breast cancer Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities Phase I Trial of a Yeast-Based Therapeutic Cancer Vaccine (GI-6301) Targeting the Transcription Factor Brachyury.Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens.Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.Activated cytotoxic lymphocytes promote tumor progression by increasing the ability of 3LL tumor cells to mediate MDSC chemoattraction via Fas signaling.Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin.Samarium-153-EDTMP (Quadramet®) with or without vaccine in metastatic castration-resistant prostate cancer: A randomized Phase 2 trial Sublethal exposure to alpha radiation (223Ra dichloride) enhances various carcinomas' sensitivity to lysis by antigen-specific cytotoxic T lymphocytes through calreticulin-mediated immunogenic modulation.nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings Recent advances in the use of therapeutic cancer vaccines in genitourinary malignancies.Immunomodulatory effects of radiation: what is next for cancer therapy?Calreticulin, a therapeutic target?Multifunctional T Lymphocytes Generated After Therapy With an Antitumor Gallotanin-Rich Normalized Fraction Are Related to Primary Tumor Size Reduction in a Breast Cancer Model.Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma.Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.Chordoma: The Quest for Better Treatment Options.

P2860

Q26748822-AED4B68F-880B-44E6-97AA-12CC26CA754E Q26851710-97CBC874-AF05-46C6-AED5-29C75488A9D7 Q33275671-31B64568-B382-4D2A-AFE9-8FCFA7FCBEFA Q33878572-6CB22A7B-7E07-4F9B-B43B-DD4E287D69A5 Q36286833-2BAE2F1C-3F1D-4D2F-927D-33CA1D4444B3 Q36302820-E7608361-A247-4906-8AB2-E2702FB62E9D Q37269053-AEE9603A-70FD-4D32-840F-48C05FCE5A34 Q37684364-7E129C05-72F0-4120-8BE5-8FA900F3037E Q37686296-D3FE412B-F375-40B1-A521-E8F156D257A7 Q37715554-508EDC61-8AEE-473E-8E1F-330AF42626DB Q38248440-1A1542B3-0A45-4410-BFE9-E8B91DE61FE4 Q38654155-05377B5B-6944-435F-95DC-7902323B1506 Q38766974-F3FE55F4-4A74-4261-ABCF-2B1ECC5F4E3B Q38848418-BAE69663-EE03-439E-AC7C-D30F528F81D3 Q39190801-30D5A0AD-8F76-4C37-995F-512A7E75F4EF Q45998119-3625145C-E34E-4813-9ADF-CDF4036027C6 Q51034581-D4C47A27-A3C2-4616-A4D3-00F38E970811

P2860

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.

http://www.wikidata.org/entity/Q37515914

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.

@en

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.

@nl

type

label

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.

@en

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.

@nl

prefLabel

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.

@en

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation.

@nl

P1433

Q37515914-BB2BAB50-C393-408D-8272-40AFF25F5787

P1476

Q37515914-E850B498-5878-4A2B-B155-3A8FF4E1FB73

P2093

Q37515914-3BA2164C-DA73-49D8-A301-F5A18BDAFB2B

Q37515914-6DA193A6-025E-4518-A3A0-475B8F1FB7F4

Q37515914-A28D4229-3FFC-4533-8346-8783C7A1CD3B

P2860

Q37515914-4CA076D2-C179-447A-B4B2-95263031941C

Q37515914-5ADF4F6E-43F4-44B8-A28F-05EC780D2BCF

Q37515914-71622980-7574-4746-BDA0-0E36B6E0E209

Q37515914-AF09E9CE-4AC1-4082-A0C0-D7DCC7A34812

Q37515914-C9A5273F-08B2-4729-8806-69F77DCFEFEB

Q37515914-D483E1E4-73FF-4DD2-B4E7-E4AEDBEA1AB0

Q37515914-F5049545-A673-4EF0-9C2B-1F9AB829AD12

Q37515914-F7497A52-206A-49D8-980E-3BC3ACD259D3

P304

Q37515914-61DFD8F1-DF31-4DC8-889C-F58CFE99C444

P31

Q37515914-C697F756-A342-48A6-8B1C-F089C58220FC

P356

Q37515914-A2A01A51-D251-43DA-91EB-6EFE895B8BE7

P433

Q37515914-1D2F41C1-3B7F-4952-A5CB-D6D7D487EF02

P478

Q37515914-B00B926F-508B-450B-B441-3DFDD7630D4F

P50

Q37515914-5495795A-75C7-47C4-836A-2B8406B9A396

P577

Q37515914-762D71F7-1F57-4074-8815-CE2007243A32

P5875

Q37515914-126B771F-ABC4-411C-8FD2-CDE4880DC36E

P698

Q37515914-FB8E41F7-02D7-41C2-BF32-4AD62A0BAD13

P932

Q37515914-670C01DD-C98E-453C-B49A-B9A124B303C0

P356

P1433

P1476

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation

@en

P2093

Andressa Ardiani

http://www.w3.org/2001/XMLSchema#string

Anna Kwilas

http://www.w3.org/2001/XMLSchema#string

James W Hodge

http://www.w3.org/2001/XMLSchema#string

P2860

Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses

Immunogenic cell death in cancer therapy

Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.

Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy.

The tipping point for combination therapy: cancer vaccines with radiation, chemotherapy, or targeted small molecule inhibitors

Antigen presentation machinery (APM) modulation and soluble HLA molecules in the tumor microenvironment: do they provide tumor cells with escape mechanisms from recognition by cytotoxic T lymphocytes?

Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.

Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model.

P304

e26937

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4161/ONCI.26937

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Sofia R Gameiro

P577

2013-11-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260109514

http://www.w3.org/2001/XMLSchema#string

P698

24498561

http://www.w3.org/2001/XMLSchema#string

P932

3902115

http://www.w3.org/2001/XMLSchema#string